Tranexamic AcidThird Party Manufacturing in India

Tranexamic Acid works as a potent antifibrinolytic agent by competitively and reversibly blocking the lysine-binding sites on plasminogen molecules. This synthetic lysine analogue occupies the high-affinity binding site on plasminogen that is responsible for its attachment to fibrin, thereby preventing the conversion of plasminogen to the active proteolytic enzyme plasmin. By inhibiting plasmin formation, tranexamic acid preserves the structural integrity of fibrin clots and prevents their premature degradation.

At higher concentrations, tranexamic acid directly inhibits plasmin activity and can block the active site of urokinase plasminogen activator. This dual mechanism ensures robust clot stabilization across a range of clinical scenarios. The drug is approximately six to ten times more potent than the older antifibrinolytic aminocaproic acid due to its stronger binding affinity for plasminogen.

Unlike anticoagulants that prevent clot formation, tranexamic acid specifically targets the fibrinolytic system that breaks down existing clots. This selectivity allows it to reduce excessive bleeding without promoting de novo thrombus formation in most patients. It is evenly distributed into various tissues including cerebrospinal fluid and aqueous humor, and is primarily eliminated unchanged in the urine.

Therapeutic Uses

Tranexamic Acid is prescribed for the treatment and prevention of:

• Heavy Menstrual Bleeding (Menorrhagia): Reduces menstrual blood loss by 40 to 60 percent, providing a non-hormonal option for women with heavy periods.
• Trauma-Associated Hemorrhage: Proven to reduce all-cause mortality in trauma patients when administered within three hours of injury, as demonstrated by the landmark CRASH-2 trial.
• Postpartum Hemorrhage: Recommended by WHO and RCOG guidelines for management of obstetric bleeding, reducing death due to bleeding in women following childbirth.
• Surgical Bleeding: Used perioperatively in cardiac, orthopedic, hepatic, and gynecological surgeries to reduce blood loss and transfusion requirements.
• Hereditary Angioedema: Long-term prophylaxis to reduce the frequency and severity of angioedema attacks.
• Dental Procedures: Prevents bleeding in patients with hemophilia or those on oral anticoagulants undergoing tooth extraction.
• Epistaxis and Hemoptysis: Controls recurrent nosebleeds and coughing up blood in appropriate clinical settings.

Why Manufacturers Choose Tranexamic Acid

Tranexamic Acid is one of the most widely prescribed antifibrinolytic medications globally, with inclusion in the WHO Model List of Essential Medicines. Its strong evidence base, demonstrated in large-scale clinical trials, ensures consistent demand from hospitals, surgical centers, and gynecology practices. The molecule is well-characterized with stable synthetic processes, making it cost-effective to manufacture at scale.

This makes Tranexamic Acid one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented pharmaceutical companies.